The IDI

Valuate Health Consultancy
  • 5,0 (3)
  • CIÊNCIAS DA VIDA
  • MENSAL

The IDI is a podcast by and for market access professionals. Each episode, we conduct in-depth interviews to get payer insights that help you optimize your value strategy and commercialization – and give people access to the heath care they deserve. The IDI is presented by Valuate Health Consultancy. Follow Valuate on LinkedIn or visit us at ValuateHealth.com to learn more.

  1. 01/05/2024

    Message Testing and Market Access

    What message is your prescription drug delivering? Before manufacturers debut a new prescription drug they need to create a strategy to optimize coverage and commercialization. But part of that strategy consists of crafting a message that resonates with patients, providers and payers. And that’s where a lot of manufacturers get tripped up.  Alex Mindlin of Valuate Health joins The IDI to explain how she validates manufacturers’ value messaging by combining strategic content and market research -- what she calls “creative market research.” Follow Alex on LinkedIn. Follow Valuate Health on LinkedIn or on the web.

    25min

  2. 01/04/2024

    Social Determinants of Health and Market Access

    Many pharmaceutical companies say attacking health inequities is a strategic objective, but addressing the topic is hard to do. Why is this so?  This episode's guest, Elisa Remoundos,  Senior Vice President and Group Creative Director for Entrée Health, believes that for pharma and market access to tackle health inequities they need to rethink the social determinants of health that can have a huge impact on adherence, compliance, health outcomes, and societal burdens. Elisa also wrote about SDoH and market acccess here.  Follow Elisa on LinkedIn.  Follow Valuate on LinkedIn or learn more here.

    25min

  3. 04/03/2024

    A Payer’s Perspective on Prior Authorization

    What do payers think about prior authorization?  Dr. Andrew Hertler is Chief Medical Officer at Evolent Health. He recently co-authored an op-ed about prior authorization, touching on gold-carding, a controversial solution to addressing prior authorization challenges.  Joining Hertler is regular guest John Hennessy, a Principal with Valuate.  Topics include: Why exceptions can sometimes be problematic.What happens after a prior authorization is rejected.Pathways: Who makes the decisions? How are they updated?How should pharma  think about payers?What can manufacturers and market access do to help pathways?Follow Andrew on  LinkedIn.  Follow Valuate on LinkedIn Learn more about Valuate.

    36min

  4. 31/01/2024

    What Do Payers Think About Market Access?

    It’s no secret that pharmaceutical manufacturers and payers don’t always see eye to eye. But in order for pharma market access to do its job it needs to better understand payers -- how  they think, what keeps them up at night, and what’s trending. That’s why Valuate conducted its Second Annual Market Access survey late last year. The goal was to better understand payer perspectives on everything from the Inflation Reduction Act to biosimilars to gold bagging.  Tony Gibson, a Principal with Valuate Health, returns to The IDI to break down the results. You can also contact Tony if you want an exclusive readout of the survey. Follow Tony on  LinkedIn.  Follow Valuate on LinkedIn Learn more about Valuate.

    27min

  5. 03/01/2024

    Is Hub Optimization the Key for Drug Launches?

    So you’ve developed a great new specialty drug but will patients and providers utilize your therapy correctly? A great hub can  help but implementing one is no easy task.  Justine Hughes, a vice president with Archbow Consulting, joins The IDI to explain where pharma and biotech hubs stumble -- and how they can succeed.  Follow Justine Hughes on LinkedIn.  Follow Valuate on LinkedIn.  Learn more about Valuate.

    27min

  6. 01/12/2023

    Politics and Prescription Drugs: What's Ahead in 2024

    The new year will be critical for pharma and market access. The industry will need to turn its attention back to the Inflation Reduction Act as the first 10 drugs are up for negotiation with the feds. Plus, there's the small matter of electing a new President.  Al Jackson joins the IDI to help break down what it all means and where all this activity in Washington is headed. An attorney by training, Al was most recently EVP and head of health and public affairs at Ketchum. Follow Al Jackson on LinkedIn.  Follow Valuate on LinkedIn.  Learn more about Valuate.

    31min

  7. 12/10/2023

    Fighting Breast Cancer is Not a Solitary Struggle

    Getting a cancer diagnosis and navigating treatment can be a lonely experience, as guest Cora Meese shares on this episode of The IDI.  Thanks to early detection, Cora is now a breast cancer survivor, but she didn’t get there on her own.  With the help of friends and family, including podcast guest John Hennessey, Cora was able to successfully navigate her oncology journey, and connect with groups like the Young Survival Coalition.  As we recognize Breast Cancer Awareness Month, listen to Cora share her personal journey and reflect on how her insider knowledge as a cancer patient has impacted her work in market access.   Cora Meese, MBA, is Executive Vice President, Director of Client Services, for Entree Health.  John Hennessy is a principal with Valuate Health and Vice President of the Board of Directors of the Young Survival Coalition.  Follow Valuate on LinkedIn.

    28min

  8. 02/10/2023

    Why Prior Authorization Matters for Pharma

    It’s hard to think of an aspect of health care more vexing than prior authorizations. In fact, prior authorizations are so frustrating that Congress is looking into a legislative solution.  This episode of The IDI we have two guests to explain the state of prior authorization and how to improve the process.  John Hennessy is a principal with Valuate Health with a background in oncology and cancer care. Syam Palakurthy is co-founder and CEO of SamaCare, a company that streamlines the prior authorization process for medical benefit drugs.  Follow Valuate on LinkedIn.

    31min
Ver tudo (26)

Classificações e avaliações

5
de 5
3 avaliações

Sobre

The IDI is a podcast by and for market access professionals. Each episode, we conduct in-depth interviews to get payer insights that help you optimize your value strategy and commercialization – and give people access to the heath care they deserve. The IDI is presented by Valuate Health Consultancy. Follow Valuate on LinkedIn or visit us at ValuateHealth.com to learn more.

Informações

  • Criado por
    Valuate Health Consultancy
  • Anos de atividade
    2022 - 2024
  • Episódios
    26
  • Classificação
    Livre
  • Site do podcast
    The IDI